Passage Bio and Remix Therapeutics Announce Merger to Advance RNA Therapies

Key Facts

In a move reflecting the ongoing trend of biotech consolidation to bolster clinical pipelines, Passage Bio and Remix Therapeutics have announced a definitive merger agreement to form a combined entity. According to reports, the merged company will operate under the Remix Therapeutics name, focusing its primary efforts on developing innovative therapies designed to reprogram RNA processing. This merger aims to leverage combined resources to advance a pipeline of small molecule therapies that address disease drivers at their genetic origin.

This strategic alignment comes as the biotechnology sector prioritizes operational efficiency, following major industry moves such as Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics to strengthen neuro-drug portfolios per Reuters reports. The combined entity seeks to utilize Remix’s proprietary technology platform, which enables access to disease targets previously considered "undruggable," positioning the firm competitively within the expanding RNA therapeutics market.

Operationally, investors are now focusing on the merger's closing timeline and its impact on the combined company's cash runway. Looking at the economic calendar, global market participants are awaiting consumer confidence data from the US and Eurozone on June 22, 2026, which may influence risk appetite in the healthcare sector.